“The most effective way to move from target identification to the clinic is to identify already approved drugs with the potential for activating or inhibiting unintended targets.” (S Dakshanamurthy et al, J Med Chem, 2012, 55(15), pp6832–6848.)
Introducing PRO Compliance
The essential resource for in-house professionals
Become your target audience’s go-to resource for today’s hottest topics.
Understand your clients’ strategies and the most pressing issues they are facing.
Keep a step ahead of your key competitors and benchmark against them.
Power up your legal research with modern workflow tools, AI conceptual search and premium content sets that leverage Lexology's archive of 900,000+ articles contributed by the world's leading law firms.
Questions? Please contact [email protected]
Register
To view this article you need a PDF viewer such as Adobe Reader.
“The most effective way to move from target identification to the clinic is to identify already approved drugs with the potential for activating or inhibiting unintended targets.” (S Dakshanamurthy et al, J Med Chem, 2012, 55(15), pp6832–6848.)
If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].
"Lexology is a good barometer of a firm's expertise as the articles showcase a firm's understanding of the issues involved and how up to date their knowledge is. It's a good one stop solution where one is able to view the same law/cases from different perspectives; on the whole I would rate Lexology as a good service."